Enalapril maleate orally disintegrating tablets

This product is an angiotensin converting enzyme inhibitor. After oral administration, it is hydrolyzed into Enalaprilat in the body, which strongly inhibits angiotensin converting enzyme, reduces the content of angiotensin II, causes systemic vasodilation, and causes blood pressure reduction. It has a significant antihypertensive effect on rat models of renal hypertension II, renal hypertension I, and spontaneous hypertension.

Chemical name: N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-proline maleate. Chemical name: N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-proline maleate Molecular weight: C20H28N2O5·C4H4O4

This product is white tablets

1. All stages of essential hypertension. 2. Renal vascular hypertension. 3. All levels of heart failure For patients with symptomatic heart failure, it is also suitable for: improving survival rate; delaying the progression of heart failure; reducing hospitalization due to heart failure. 4. Prevention of symptomatic heart failure For patients with asymptomatic left ventricular dysfunction, it is suitable for: delaying the progression of symptomatic heart failure; reducing hospitalization due to heart failure. 5. Prevention of coronary ischemic events in patients with left ventricular dysfunction, it is suitable for: reducing the incidence of myocardial infarction; reducing hospitalization due to unstable angina.

The absorption of this product is not affected by food, so it can be taken before, during or after meals. This product is an orally disintegrating tablet. Place the product on the tongue. The tablet will disintegrate completely in about half a minute and can be swallowed. No water is needed to take it. Slight movement of the mouth and tongue can accelerate the disintegration of the tablet and further shorten the medication process. 1. Primary hypertension: Depending on the severity of hypertension, the starting dose is 10 mg to 20 mg, once a day. For mild hypertension, the recommended starting dose is 10 mg per day. For the treatment of other degrees of hypertension, the starting dose is 20 mg per day. The commonly used maintenance dose is 20 mg per day, which can be adjusted to a maximum dose of 40 mg per day according to the patient's needs. 2. Renovascular hypertension: Because the blood pressure and renal function of this type of patient may be particularly sensitive to angiotensin-converting enzyme inhibitors

Symptoms may include dizziness, headache, drowsiness, dry mouth, fatigue, upper abdominal discomfort, nausea, palpitations, chest tightness, cough, flushing, rash, and proteinuria. Reduce the dosage if necessary. If leukopenia occurs, stop taking the drug.

Patients who are allergic to this product or have bilateral renal artery stenosis should not use this product. Patients with severe renal impairment should use it with caution.

Precautions for children: Use with caution in children. Precautions for pregnancy and lactation: Use with caution in pregnant and lactating women. Precautions for the elderly: Not yet clear.

1. Used with diuretics, the antihypertensive effect is enhanced, but serious hypotension must be avoided. 2. Used with potassium-retaining diuretics, this product can reduce potassium loss, but used with potassium-retaining diuretics, it can increase blood potassium. 3. Used with lithium preparations, this product can cause lithium poisoning, but the toxic reaction disappears after stopping the drug.

seal.

10 mg

36 months

Qingdao Guohai Biopharmaceutical Co., Ltd.

• Founded in:

  2010-01-04

• Address:

  No. 16 Fengjin Road, Chengyang District, Qingdao City, Shandong Province

• Tax NO.:

  91370214697187900G

• Registered Funds:

  68.1 million yuan

• Website:

  Log in to view

• Email:

  Log in to view